While the extracellular antigen-targeting domain typically consists of a single-chain variable fragment (scFv) derived from an antibody, novel approaches for the antigen-targeting domain are being developed, including the use of ligand-receptor interactions to facilitate binding, such as the use of APRIL-based CARs for dual targeting of BCMA and TACI in MM (4, 5). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.